Pricing Log in Create free account
Friday 6 November 2026 Export ARAY’s income statement to Excel — free account

Accuray Incorporated

ARAY Healthcare Medical Devices

Accuray Incorporated’s revenue for fiscal 2026 (year ended June 2026) was $401.9 million, down 12.3% from fiscal 2025.

Revenue
−7.90%
EPS
+138.9%
Free cash flow
−138.3%
Total debt
−25.4%

Quarter to September 2026, against a year earlier

0.11 0.01 −8.33%
Market cap
$14.8M
P/E
0.0×
Fwd P/E
−1.3×
Dividend yield
—
F-score
1/9
Altman Z
−0.78
Beneish M
−3.08
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.13
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — 2 — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 17.35%

Capital & Financial Ratios $m

Size
Market Cap 14.82
Revenue ttm 394.53
Net income ttm (17.38)
Free cash flow ttm (27.05)
Net debt Q 94.97
Valuation
P/E 0.00
Forward P/E (1.27) (negative: loss-making)
Price / sales 0.04
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.29
Financial health
Current ratio Q 1.56 (at or above 1.5: strong)
Debt / equity Q 1.79
Interest coverage Q (3.09)
Growth
Revenue growth Q −7.90% (below 0%: shrinking)
Operating income growth Q −222.66% (below 0%: shrinking)
EPS, this year −1,950.00% (below 0%: weak)
EPS, next year A +41.46% (at or above 15%: strong)
Revenue, next year A +2.75%
EPS, past 5 yrs —
EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.2×, against a ten-year median of 0.8×; over the ten years it ranged from 0.2× in 2026 to 1.4× in 2016.
P/S against its own 10 years 0.04%
10-year low 10-year high
P/B against its own 10 years 0.04%
10-year low 10-year high
EV/Sales against its own 10 years 0.04%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2024 2025 2026 Q'26
Cash 69 58 41 —
Receivables 92 83 67 —
Inventory 138 141 147 146
Other — — — —
323 317 288 266
2024 2025 2026 Q'26
Payables 50 34 41 33
ST’ Debt — — — —
Other 14 12 10 —
195 193 191 170

Compound Annual Growth %

10y 5y 3y
Sales 0.08% 0.28% (3.52%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (3.52%) (9.54%) (8.06%)

Earnings Trends EPS, adjusted, against the consensus

Q4 FY25 Estimate 0.03 Actual 0.00

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q1 FY24 −0.04 −0.04 Met by 0.00
Q2 FY25 −0.01 0.02 Beat by 0.03
Q3 FY25 −0.05 −0.01 Beat by 0.04
Q4 FY25 0.03 0.00 Miss by 0.03

EPS $

Sep Dec Mar Jun Year
’26 0.07 — — — —
’26 (0.18) (0.11) (0.09) (0.02) (0.40)
’25 (0.04) 0.02 (0.01) 0.01 (0.02)
’24 (0.03) (0.10) (0.06) 0.03 (0.16)
’23 (0.06) (0.02) 0.01 (0.03) (0.10)
’22 (0.01) 0.00 (0.01) (0.04) (0.06)
’21 0.00 0.05 0.00 (0.12) (0.07)
Fiscal quarters ending in the months shown.

Revenue $m

Sep Dec Mar Jun Year
’26 87 — — — —
’26 94 102 105 101 402
’25 102 116 113 128 459
’24 104 107 101 134 447
’23 96 115 118 118 448
’22 107 116 96 110 430
’21 85 97 103 111 396
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Sep Dec Mar Jun Year
’26 (4) — — — —
’26 12 (16) (6) 2 (7)
’25 (7) 2 18 (10) 3
’24 (9) (5) (8) 10 (12)
’23 0 (18) 25 9 16
’22 (9) 33 (22) (5) (2)
’21 (3) 19 16 6 39
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Sep Dec Mar Jun Year
’26 (4) — — — —
’26 10 (19) (6) 2 (13)
’25 (8) 1 17 (11) (1)
’24 (10) (6) (9) 9 (16)
’23 (1) (20) 23 1 3
’22 (10) 32 (23) (6) (7)
’21 (3) 19 16 5 36
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to June

Ten-year view Analyst estimates Powerpack
Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 TTM Sep ’26 Trend 10 yrs 2027e 2028e 2029e Next 3/yr
Income, $m
Income, $m Revenue 383 405 419 383 396 430 448 447 459 402 395 +0.5% 413 423 — +2.5%
Gross margin, % 36.86 39.93 38.84 39.10 40.25 37.21 34.40 32.01 32.05 27.73 0.00 (9.1) pt
EBT (29) (23) (14) 6 (5) (2) (7) (12) 1 (47) (15) +5.8%
EBT margin, % (7.44) (5.69) (3.43) 1.49 (1.15) (0.47) (1.52) (2.65) 0.25 (11.75) (3.90) (4.3) pt
Net income (30) (24) (16) 4 (6) (5) (9) (16) (2) (49) (17) +5.8%
Per share, $
Per share, $ Revenue 4.65 4.77 4.79 4.26 4.31 4.67 4.72 4.54 4.46 3.28 2.85 (3.8%)
Earnings (0.36) (0.28) (0.19) 0.04 (0.07) (0.06) (0.10) (0.16) (0.02) (0.40) (0.15) +1.2%
Cash flow 0.00 0.22 (0.34) (0.02) 0.42 (0.03) 0.16 (0.12) 0.03 (0.06) (0.17) +32.2%
Capex (0.06) (0.08) (0.05) (0.04) (0.03) (0.05) (0.13) (0.04) (0.04) (0.05) (0.03) (3.4%)
Free cash flow (0.07) 0.14 (0.39) (0.06) 0.39 (0.08) 0.03 (0.16) (0.01) (0.10) (0.20) +4.6%
Book value 0.56 0.57 0.57 0.71 0.75 0.58 0.57 0.46 0.79 0.34 0.38 (5.5%)
Shares, m 82 85 87 90 92 92 95 98 103 123 127 +4.5%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 67.67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.8
P/S 1.02 0.86 0.82 0.48 1.05 0.42 0.82 0.39 0.31 0.08 0.04 0.6
P/B 8.42 7.12 6.86 2.87 6.04 3.39 6.84 3.84 1.73 0.76 0.29 4.8
EV/Sales 0.87 0.95 0.99 0.69 1.18 0.61 1.00 0.60 0.45 0.34 0.17 0.8
EV/FCF (55.99) 34.47 (11.98) (47.59) 13.02 (36.16) 157.05 (17.23) (139.68) (10.61) (2.54) (11.5)
Cash, $m
Cash, $m Operating cash flow 0 18 (30) (1) 39 (2) 16 (12) 3 (7) (23) +38.2%
Capex (5) (7) (4) (4) (2) (5) (13) (4) (4) (6) (4) +1.0%
Free cash flow (6) 12 (34) (5) 36 (7) 3 (16) (1) (13) (27) +9.4%
Balance, $m
Balance, $m Working capital 25 115 152 175 160 142 139 128 125 96 96 +16.4%
Net debt (57) 38 73 81 53 83 82 95 66 105 95 n/m
Shareholders’ equity 47 49 50 64 69 53 54 45 81 42 53 (1.2%)
Returns, %
Returns, % ROA (6.76) (6.09) (4.02) 0.82 (1.30) (1.12) (1.95) (3.28) (0.34) (10.77) (4.10) (4.0) pt
ROIC 0.00 (2.73) 0.30 5.43 11.40 3.74 1.10 0.22 3.33 (11.25) (21.79) (11.2) pt
ROE (55.71) (50.23) (33.36) 6.74 (9.53) (8.76) (17.37) (31.49) (2.52) (80.08) (30.23) (24.4) pt
People
People Employees 944 998 947 932 995 1,044 1,024 987 990 809 — (1.7%)
Revenue/emp, $m 0.41 0.41 0.44 0.41 0.40 0.41 0.44 0.45 0.46 0.50 — +2.3%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Jun 2026 · latest quarter Sep 2026 · fundamentals updated 6 Nov 2026

Accuray Incorporated vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ALUR Allurion Technologies, Inc. $16.7M — (loss-making) — (loss-making) −47.19% (below 0%: shrinking) n/m +65.98% (above 0%: growing) 41.70% (126.60%) Compare
LFWD Lifeward Ltd. $16.3M — (loss-making) — (loss-making) +15.71% (above 0%: growing) n/m −52.77% (below 0%: shrinking) 40.90% (62.69%) Compare
ARAY Accuray Incorporated $14.8M — (loss-making) — (loss-making) −7.90% (below 0%: shrinking) n/m −138.30% (below 0%: shrinking) 0.00% (42.19%)
CTSO Cytosorbents Corporation $14.5M — (loss-making) — (loss-making) +0.17% (above 0%: growing) n/m +64.90% (above 0%: growing) 73.18% (27.39%) Compare
RBOT Vicarious Surgical Inc. $14.3M — (loss-making) — — n/m +47.33% (above 0%: growing) 0.00% 0.00% Compare
HSCS HeartSciences Inc. $13.3M — (loss-making) — (loss-making) −46.15% (below 0%: shrinking) n/m +18.18% (above 0%: growing) 61.90% (139,957.14%) Compare
PETV PetVivo Holdings, Inc. $12.9M — (loss-making) — (loss-making) +13.48% (above 0%: growing) n/m +40.13% (above 0%: growing) 66.14% (476.54%) Compare
ITOC iTonic Holdings Ltd. $12.4M — — — — — — — Compare
PAVM PAVmed Inc. $12.4M — (loss-making) — (loss-making) +450.00% (above 0%: growing) n/m −125.63% (below 0%: shrinking) (269.70%) (21,278.79%) Compare
Median of peers $13.8M — — +6.83% — +40.13% 41.70% (126.60%)

All 149 Medical Devices stocks →

Pay and ownership Proxy statement filed 16 October 2026

Ownership

Directors and executive officers, together 3.50%
The TCW Group, Inc., on behalf of the TCW Business Unit 23.00%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Accuray Incorporated (ARAY) Latest News

5 Nov

Impact 3 · · The Motley Fool transcript
Impact 3 · · GuruFocus.com transcript

4 Nov

Impact 3 · · Associated Press
Impact 3 · · PR Newswire

21 Oct

Impact 3 · · PR Newswire

6 Oct

Impact 4 · · PR Newswire

28 Sep

Impact 3 · · medicaldevice-network.com

27 Sep

Impact 4 · · PR Newswire

14 Sep

Impact 3 ·

11 Sep

Impact 4 ·

28 Aug

Impact 3 ·

26 Aug

Impact 4 · · The Motley Fool transcript

20 Aug

Impact 4 ·

19 Aug

Impact 3 · · Moby
Impact 3 ·

30 Jul

Impact 3 ·

29 Jul

Impact 4 ·

15 May

Impact 3 · · PR Newswire

12 May

Impact 3 · · Insider Monkey

6 May

Impact 4 · · The Motley Fool transcript
Impact 4 · · MarketBeat
Impact 4 · · PR Newswire

6 Apr

Impact 3 · · PR Newswire

4 Feb

Impact 4 · · MarketBeat transcript
Impact 4 · · PR Newswire
Impact 3 · · The Motley Fool transcript
Impact 3 · · Associated Press FinanceAssociated Press FinanceAssociated Press FinanceAssociated Press FinanceAssociated Press FinanceAssociated Press FinanceMT NewswiresMT Newswires

11 Jan

Impact 3 · · Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.

15 Dec

Impact 4 · · PR Newswire

13 Dec

Impact 3 · · Simply Wall St.
stockrow.com/ARAY · Data as of Nov 6, 2026 · For information only; not investment advice. · © 2026 stockrow.com